Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Current Assets (2016 - 2025)

Surgery Partners (SGRY) has disclosed Current Assets for 12 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 2.8% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 2.8% year-over-year, with the annual reading at $1.2 billion for FY2025, 2.8% up from the prior year.
  • Current Assets hit $1.2 billion in Q4 2025 for Surgery Partners, up from $1.1 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.2 billion in Q4 2025 to a low of $738.3 million in Q3 2022.
  • Historically, Current Assets has averaged $954.5 million across 5 years, with a median of $941.6 million in 2021.
  • Biggest five-year swings in Current Assets: soared 65.6% in 2021 and later dropped 17.26% in 2022.
  • Year by year, Current Assets stood at $946.1 million in 2021, then fell by 2.65% to $921.0 million in 2022, then dropped by 2.82% to $895.0 million in 2023, then rose by 25.07% to $1.1 billion in 2024, then increased by 2.8% to $1.2 billion in 2025.
  • Business Quant data shows Current Assets for SGRY at $1.2 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.1 billion in Q2 2025.